Clinical Trial Update: The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases [EARLY_Phase 1]

View source ↗

Summary

This clinical trial update covers the safety and potential efficacy of anti-CD19 CAR-T cells for relapsed/refractory autoimmune diseases, with the study current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Antiphospholipid Syndrome
• Inflammatory Myopathy
• Sjögren Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• Anti-CD19 CAR T cells (CD19-directed CAR T cells)

Snippet

Sponsor: First Affiliated Hospital of Wenzhou Medical University | Conditions: Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome | EARLY_Phase 1 | Status: NOT_YET_RECRUITING